VC/PE/M&A. Healthcare Weekly(2018.01.15)

 Mon Jan 15 14:18:36 CST 2018 A- A+

作者:克莱尔

本期内容概览

  • 被巨头辉瑞看准的药物发现能力!Adapsyn获得1.62亿美元投资以发掘药物中的“遗珠”。
  • 联合韩国医美力量,这家即将IPO的加州公司能否打破Allergan的肉毒素神话?
  • 碧莲盛植发获5亿投资,华盖资本重金打造植发龙头
  • 与其大而无当,不如小而美——EHR服务商Practice Fusion成功被Allscripts收购。
  • 大刀阔斧做改革,瞄准药物求发展——GSK的CEO能否将革新精神贯彻到底?

私募融资 & IPO

1. 被巨头辉瑞看准的药物发现能力!加拿大公司Adapsyn获得1.62亿美元投资以发掘药物中的“遗珠”

概要:在一群活体有机物中找到合适的候选药物并非易事,但是2016年成立于加拿大安大略省的一家生物科技公司Adapsyn Bioscience研发出了一个可以更加高效地甄选此类药物的系统,成功吸引了制药巨头辉瑞的风头部门Pfizer R&D Innovate的注意。后者和Genesys Capital共同投资了这家公司,且额外拨出1.62亿美元以使用Adapsyn的微生物菌种相关药物检索平台。通过这笔交易将助力Adapsyn的大数据挖掘以及人工智能技术在药物发现方面的应用,以期重新找到之前被忽略的“遗珠”,并赋予被投公司和辉瑞以在合作中发现的新化合物及其衍生物的独家权利。

相关报道:

Adapsyn signs $162M microbe-mining deal with Pfizer

Jan 10, 2018

Finding drugs amongst the metabolic soup of living organisms is a tough task, but Canadian biotech Adapsyn Bioscience has developed a system that could sift out promising candidates more quickly—catching the eye of a pharma partner. Pfizer’s venture arm Pfizer R&D Innovate just stumped up a financing round for the Hamilton, Ontario-based star-up along with Genesys Capital, which will fund its internal drug discovery efforts. And the big pharma has also earmarked $162 million for a project that will use Adapsyn’s platform to search through its collection of microbial strains. The deal, which includes unspecified upfront cash, will apply Adapsyn’s big data-mining and artificial intelligence technology to try to identify previously undiscovered natural products, with both companies having “exclusive rights to pursue select novel compounds and their derivatives identified through the collaboration.” If Pfizer chooses to take any forward to market, it is in line for pay milestones and royalties—with a reciprocal arrangement if Adapsyn goes down that route. Adapsyn was set up in 2016 to build on work carried out at McMaster University by its founder and chief scientific officer Nathan Magarvey, Ph.D., who is an associate professor at McMaster and has previously held positions at Harvard Medical School and Wyeth Research. Magarvey’s work focuses on mining microbial genomes for natural product biosynthetic gene clusters that may code for potential novel drug candidates. The possible disease targets in the Pfizer collaboration have not been disclosed. "Discovering truly novel compounds that exhibit new pharmacological signatures from natural products has historically been a very time- and labor-intensive process," said Edmund Graziani, head of synthetic biology and natural products at Pfizer. "Adapsyn's technology could potentially help take much of the guess work out of the process, and help reveal novel chemistry and biology from our natural product samples." Pfizer’s executive director of worldwide business development is joining Adapsyn’s board, along with Genesys Capital co-founder and managing director Kelly Holman.

Source: FierceBiotech

https://www.fiercebiotech.com/biotech/adapsyn-signs-162m-microbe-mining-deal-pfizer

2. 联合韩国医美力量,这家即将IPO的加州公司能否打破Allergan的肉毒素神话?

概要:位于美国加州尔湾的Evolus近期提交了7500万美元的IPO申请,用于其除皱药物DWP-450的审批、支付给韩国合作者以里程碑款项,以及强化自身的销售和市场团队。通过此次募资,这家专门研发肉毒素biosimilar copy的公司将有可能挑战Allergan在美国及国际市场的除皱业务的领先地位。Evolus在2013年从韩国公司Daewoong手中获得授权,开展了三次临床三期试验,从而研发肉毒素的对标药物DWP-450。其中两个临床三期试验显示,DWP-450在除皱方面相对于无效对照剂效果更好,而剩下那个三期试验则显示其药物相对于肉毒素有独特优势。在和肉毒素的对比试验中,那些使用了DWP-450的患者中87%有所反应,而接受了Allergan的肉毒素的患者只有83%有所反应。Evolus利用这些数据在美国、欧盟和加拿大寻求药物批准,FDA的相关决定将在今年5月15日之前下发,而欧盟的决定则预计在今年下半年公布。

相关报道:

Evolus plans $75M IPO to bring Botox biosimilar to market

Jan 10, 2018

Evolus has filed for a $75 million IPO. The financing will position Evolus to challenge Allergan’s grip on the wrinkle-busting sector by bringing a biosimilar copy of Botox to market in the U.S. and elsewhere. Irvine, California-based Evolus has taken its rival to Botox, DWP-450, through three phase 3 trials since it picked up the rights to the program from South Korea’s Daewoong in 2013. Two of the phase 3 trials showed DWP-450 is better than placebo at reducing wrinkles, while the third suggested it holds its own against Botox. In the Botox comparison trial, 87% of patients who received DWP-450 responded, compared to 83% of subjects who took Allergan’s blockbuster.

Evolus filed for approval in the U.S., European Union and Canada using the data. The first regulatory decision is due by May 15, the PDUFA date set by the FDA. A decision in Europe is expected to follow in the second half of the year. With Evolus closing in on approvals in key markets, it is seeking $75 million from public investors to support its attempt to go up against Allergan’s drug and associated marketing machine. Some of the cash will enable Evolus to complete the regulatory approval processes. Almost $14 million will go to Daewoong in post-approval milestone payments. And the rest will equip Evolus to run marketing campaigns and build a sales force. These tasks will transform Evolus. As of the end of September, Evolus had 22 employees, half of whom worked part time at the company. Evolus’ plan envisages the creation of an initial 65-person sales team. Over time, Evolus expects to grow the sales team to 150 people. The company’s ability to manage that rapid growth will influence how big a threat it poses to Allergan. Evolus’ ability to perform these tasks at all is dependent on the IPO. The biotech’s filing with the SEC states it has no cash as it is entirely dependent on its parent company, Alphaeon, which is itself majority owned by SCH-AEON. The post-IPO spending plan factors in some support from Alphaeon. But Evolus needs public investors to step up to secure the future of DWP-450 up to the initial commercialization stage.

Source: FierceBiotech

https://www.fiercebiotech.com/biotech/evolus-plans-75m-ipo-to-bring-botox-biosimilar-to-market

3. 碧莲盛植发获5亿投资,华盖资本重金打造植发龙头

概要:近日,碧莲盛植发引进了华盖资本旗下华盖医疗健康基金牵头组成的投资联合体投出的一笔战略投资,总投资金额5亿元。这是目前华盖医疗资本对医美细分领域最大的一笔战略投资,凸显了华盖资本对碧莲盛植发品牌及创始人团队的高度肯定,及对中国植发市场高速发展的强烈信心。

相关报道:

Lotus Medical and Cosmetic Group receives CNY 500m strategic investment from HG Partners

Jan 8, 2018

Lotus Medical and Cosmetic Group [Bi Lian Sheng], a Beijing-based privately held operator of hair restoration treatment centers, has received CNY 500m in strategic investment from a healthcare fund under HG Partners. HG Partners is a Beijing-based venture capital firm focusing on healthcare, TMT and cultural investments. It will hold a majority stake in Lotus after the deal. Established in 2005 by founder Lina You, Lotus now has more than 20 directly operated treatment centers across China, mainly in first and second tier cities. It now owns more than 10 hair restoration patents and brand trademarks. HG Partners confirmed the investment and added the deal will be announced soon. Lotus aims to focus on accelerating marketing activities, expanding brand operations, building up its pool of top medical talent and aggressively beefing up sales to keep its leadership position in China’s niche hair restoration sector. HG Partners will also help the company obtain access to the capital markets in the future. Lotus ranks among China’s top three hair restoration players in terms of revenue and net profit. It has been achieving rapid growth rates in the past few years, thanks to the explosive growth in demand for hair restoration. According to statistics by ISAPS (International Society of Aesthetic Plastic Surgery), China is the world’s third largest medical cosmetics market in 2016, and is estimated to have taken over the No.2 rank in 2017 by surpassing Brazil. China’s hair restoration market has great potential, with an average 21% of Chinese men suffering from hair loss,projecting the market value of hair restoration to reach at least CNY 50bn in the next few years.

HG Partners’ healthcare fund has billions of CNY under management, and its previous invested portfolio companies in the healthcare sector include BioKangtai [SHE:300601], Doctor Glasses [SHE:300622], Beijing Strong Biotechnologies [SZE:300406], Henlius Pharmaceuticals and Hainan Zhonghe Pharmaceutical, etc.

Source: Mergermarket, Chinadaily, Linkedin

http://www.linkedin.com/pulse/lotus-medical-cosmetic-group-receives-cny-500m-from-hg-md-llm/

并购

1. 与其大而无当,不如小而美——EHR服务商Practice Fusion 1亿美元成功被Allscripts收购

概要:电子医疗记录(EHR)公司Allscripts近日宣布1亿美元买下竞争者Practice Fusion,从而扩大业务范围和市场规模。在这项收购实现之前,EHR市场最大份额持有者是Epic Systems(13.5%),紧随其后的则是eClinicalWorks(10.4%)。Allscripts当时占据7.46%的份额,名列第三。不过在“吃下”第四名也就是Practice Fusion之后,Allscripts如今的市场份额将位列第一。被收购的公司Practice Fusion此前用12年的时间在EHR软件市场建立和巩固了一个独特的利润模型,为客户提供免费的、基于云的EHR基础解决方案,并通过广告和交易费获得利润。这一盈利模式为Practice Fusion在独立、小规模医疗机构中建立了良好的关系,其每个月经手的医疗服务高达3万次,患者500万人。

相关报道:

Allscripts snaps up rival Practice Fusion, the largest free EHR vendor, in $100M deal

Jan 10, 2018

Allscripts is buying competing electronic health record vendor Practice Fusion in a $100 million deal that bolsters Allscripts' reach and scale—and moves it up the ranks of the largest EHR businesses in the market. Allscripts has been the third-largest EHR vendor by market share with a 7.46% slice, followed by Practice Fusion at No. 4 with 6.34%, according to SK&A research. The largest EHR is Epic Systems with a 13.5% share and eClinicalWorks’ 10.4% share stands at No. 2. With the deal, Allscripts could eke out a lead over Epic, if it can keep its customers and PracticeFusion's, too. The buyout comes after Practice Fusion spent 12 years working to gain traction in the competitive software space, pushing a free-to-users, cloud-based solution with a revenue model built on ad sales and transaction fees. That model was unique in the EHR business: It offered the free basic software to practices with the caveat that users would see relevant promotional messages inside the electronic patient charts. Practice Fusion, for example, placed sponsored EHR advisories for vaccinations by Merck and for asthma and COPD by AstraZeneca. Practice Fusion has done well among smaller, independent physicians, building to 30,000 practices and 5 million patient visits per month. It also ranked fourth on Capterra’s 2017 list of most popular EHR software—measured as a combination of total number of customers, users and social presence—while Allscripts was No. 2 with 40,000 practices and 350,000 users. Allscripts said in a news release that the “strategic acquisition” would advance its health information technology solution strategy, adding that “Practice Fusion's EHR will complement and round out Allscripts' existing ambulatory clinical portfolio, providing a value offering and ‘last mile’ reach to the underserved clinicians in small and individual practices.” Allscripts president Rick Poulton called Practice Fusion’s technology “affordable” in the release, and when asked by FiercePharma to clarify Practice Fusion’s previously free status, an Allscripts spokeswoman said via email only that “Allscripts has nothing to add to what we announced in yesterday’s new release.” Practice Fusion was once a Silicon Valley darling—with high-profile investors including Paypal founder Peter Thiel and Kleiner Perkins—and had attracted more than $150 million in venture capital. It had even begun to plan for an IPO. However, it struggled more recently. Founder and CEO Ryan Howard stepped down in 2015, the company cut 25% of its staff in 2016, and rumors surfaced of a possible buyout by another competitor, athenahealth, according to Techcrunch.

Source: FiercePharma

https://www.fiercepharma.com/marketing/allscripts-acquires-competitor-and-largest-free-ehr-vendor-practice-fusion-cash-deal

行业

1. 大刀阔斧做改革,瞄准药物求发展——GSK的CEO能否将革新精神贯彻到底?

概要:位于自从去年3月上任以来,GSK的CEO Emma Walmsley就在公司管理层推进了大刀阔斧的改革,占尽了头条版面。这些大动作包括从阿斯利康挖来Luke Miels来负责公司的药物业务,任命曾在罗氏和Calico担任高层职位多年的Hal Barron为首席科学官等等。但是这一系列头条背后蕴含着GSK高层更深刻的变革——Emma Walmsley至今已经换掉了50名GSK高管,这一数目占公司领导团队的40%。通过一系列换血以及内外部招聘(包括从谷歌、诺华、Teva等全球顶级公司挖角),公司的业务目标也从消费扩展到了肿瘤市场。在CNBC的采访中,Emma表示GSK对于收购辉瑞的非处方药业务并不特别感兴趣,因为尽管GSK是市场领先的消费品医疗提供商,但目前最主要的目标是药物研发。

相关报道:

GlaxoSmithKline CEO reshuffles 40% of management team in bid to bring in new ideas

Jan 9, 2018

GlaxoSmithKline’s Emma Walmsley has grabbed headlines with some of the top management changes she’s made since taking over as CEO last March, namely poaching Luke Miels from rival AstraZeneca to head up pharmaceuticals and appointing Roche and Calico veteran Hal Barron as chief scientific officer. But behind the scenes, her scalpel has actually cut much deeper as she aims to reposition the struggling pharma giant. Walmsley has replaced 50 top managers—40% of GSK’s top management team. The overhaul has spanned the company’s businesses, from consumer to oncology, and includes hires from both inside and outside the company, a GSK spokesman told Fierce. And Walmsley has managed to attract executives from some of the world’s top companies, including Google, Novartis and Teva. “Beyond the operational execution short-term, it’s going to be all about R&D and preparing for the next wave of growth for GSK in the 2020s and beyond,” Walmsley said during a CNBC interview at the J.P. Morgan Healthcare Conference in San Francisco.

In addition to hiring Miels and Barron, GSK stole away two Novartis veterans: Tobias Hestler was named CFO of the consumer unit and Christine Roth has taken over the oncology business. Lisa Martin ditched Teva to become GSK's chief procurement officer and Tony Wood left Pfizer to join the company's R&D team, the spokesman reports. Roth is now helping steer GSK’s search for early-stage cancer drugs that it can license or buy to prop up its oncology pipeline. The company is embarking on that search as part of a major R&D overhaul it announced last July. That’s when Walmsley tossed 30 drug development programs and vowed to invest 80% of GSK’s research dollars in therapies to address respiratory disorders, infectious disease, cancer and inflammatory disease. The plan was unveiled after years of disappointing performance from GSK’s pharma division led major investors to pressure the board to break up the company. GSK’s stock has dropped nearly 9% since Walmsley took over last spring. GSK also created the position of chief digital officer and hired Karenann Terrell, the former chief information officer at Walmart, for the post. She has been charged with using new technology in data analytics and cloud computing to speed up drug development. The company also added Marc Speichert, formerly of Google, as its chief digital officer for the consumer unit. Walmsley was asked during the CNBC interview whether GSK might consider propping up the consumer unit even more by buying Pfizer’s over-the-counter business, which has been on the block since October. “We are one of the world leaders in consumer healthcare. We have a strong record of integrating businesses successfully, so you’d expect us to have a look at it. But frankly, we don’t need to do this deal,” Walmsley said. “We certainly won’t overpay for it. And nothing is going to cut across our number one priority, which is our pharma business, and really focusing on building that pipeline for the next wave of growth.”

Source: FiercePharma

https://www.fiercepharma.com/corporate/glaxosmithkline-ceo-reshuffles-40-management-team-bid-to-bring-new-ideas

以上,难免有疏漏或不正确之处,请多多指出,并在文下留言处留言,谢谢!

*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。
收藏
扫描二维码,关注新浪医药(sinayiyao)公众号
360°纵览医药全局,365天放送新闻时事医药资讯轻松一览
精彩不容错过。
文章评论
肖恩大侠 华盖医疗基金董事总经理,北京。 毕业于北京大学工学院医学院(医学硕士)、北京大学法学院(法学硕士)。资浅PE从业人士。躬耕于太湖,游学至未名,当过医生,学过法律,改行至风险投资,喜好读书写作,经史文集,现代科技都甚喜欢,总是怀着理想,万一,实现了呢?欢迎交流医疗、文化、消费,欢迎交流一级市场、二级市场,欢迎交流国内及海外并购。 邮箱:shawn.shiqq.com
+订阅
印象笔记
有道云笔记
微信
二维码
意见反馈